Workforce issues, staff retention and capacity continues to be a big concern for the Local Pharmaceutical Committee as it discussed the topics at a recent meeting with the Pharmaceutical Services Negotiating Committee (PSNC).
The meeting, attended by delegates from 66 LPCs, focused on the current challenges faced by community pharmacies as well as the planning for the next year.
Around 64 per cent of delegates said workforce was the top challenge faced by pharmacy contractors, and suggested reducing the migration of pharmacists to Primary Care Networks (PCNs).
Other suggestions included - "improving the development opportunities available for pharmacists and their teams, and rebranding the profession to make community pharmacy a more attractive route for young graduates."
On the development of Integrated Care Systems (ICS), the majority of respondents were positive about their LPC's engagement in the new setting.
Teva UK has alerted the Secretary of State for Health and Social Care to the problem posed by steep energy prices.
Teva's UK General Manager Kim Innes wrote to the minister seeking assurances that the distribution of medicines to patients will be safeguarded over what's likely
to be a difficult winter.
The problems posed by steep energy prices and the potential for power rationing is putting pharmacies under pressure from increased costs and the risk of losing power
supplies as a 'non-domestic' energy user, said the company.
Kim said: "In our letter to the Secretary of State we acknowledged that the government knows that medicines manufacture is strategically important and that it's a
vital component in maintaining patient health."
"But I wanted to make sure that the Secretary of State also realises the consequences of the energy crisis further down the supply chain - for example, the need for
a pharmacy to have a fridge switched on at all times for storing cold chain products."
Walgreens Boots Alliance has announced the launch of its new clinical trials business that aims to use patient data from its pharmacies to help drive up
recruitment in studies conducted by drugmakers.
With patient recruitment and enrollment remain key challenges in clinical trials, further exacerbated by the COVID-19 pandemic, the company said it can proactively
match diverse patient populations to trials across a range of disease areas based on race, gender, socioeconomic status and location with its patient reach and
access to an extensive foundation of pharmacy and patient-authorised clinical data.
The Boots owner also believes that by leveraging a tech-enabled approach to patient identification and creating a large registry of clinical trial participants,
the company will be able to reduce the time it takes to match eligible patients to clinical trials.
"Walgreens trusted community presence across the nation, combined with our enterprise-wide data and health capabilities, enables us to pioneer a comprehensive
solution that makes health options, including clinical trials, more accessible, convenient and equitable," said Ramita Tandon, chief clinical trials officer,
Walgreens.
A community pharmacist, Viral Doshi was honoured with the British Citizen Award (BCA) on Thursday (26 January) at the Palace of Westminster for transforming
his community centre into vaccination hub during Covid-19 pandemic.
Viral was presented with his Medal of Honour by Liam Sargeant, Senior Company Communications Manager, from supporters P&G and TV presenter and Patron of the BCA,
Nick Knowles, who hosted the event.
At the height of the pandemic, Viral obtained approval to transform his community centre into a vaccination hub. Located in the heart of a multi-ethnic population,
with social deprivation, surrounded by wards experiencing high rates of Covid-19. His determination to increase uptake and reduce vaccination hesitancy, led to
80,000 vaccinations being administered, the overall highest vaccination uptake in North West London.
Viral is a passionate advocate for the role that GP practices and community pharmacies can play in supporting the health agenda. His objective, to provide better
choice and access for the community have been fully met and appreciated by patients. His initiatives led to a dramatic increase in the clinical skills, knowledge
and services offered by local community pharmacies around a variety of health topics. This enabled pharmacies to adopt a holistic health approach to working with
their communities.
The General Pharmaceutical Council (GPhC) has launched a consultation on whether people agree or disagree that its hearings should continue to be held remotely when it is fair and practical to do so.
The 12-week consultation - which ends on February 8 - seeks views on a proposed permanent change to the GPhC's procedural rules which will allow it to conduct
hearings and meetings by teleconference or videolink.
The pharmacy regulator is seeking changes to enable it to continue to hold some hearings remotely in the future following positive feedback from those taking part
in hearings during the Covid-19 pandemic which the GPhC held remotely by videolink.
"In cases where the GPhC investigates a concern about a pharmacist or pharmacy technician and decides there is evidence to show that their fitness to practise may
be impaired, the case may need to be referred for a hearing before a committee," GPhC said in a statement today (November 16).
In its latest style guide for digital health writing, the NHS advises bloggers and writers to avoid using the word 'chemist' when referring to a 'pharmacy' as users are more likely to look for the latter.
Likewise, the content guide titled 'A to Z of NHS health writing' encourages writers to use 'ethnic minorities' rather than the more commonly used abbreviated forms
such as 'BAME' or 'BME'.
"Use a capital letter when you're writing about ethnicity or when you're asking users for their ethnic group," it advises, and therefore recommends writing 'Black,
Asian, African, Black British or Caribbean' or 'people from a White British background'.
In a further chapter on 'Ethnicity, Religion and Nationality,' it notes that a writer should "only refer to people's ethnic heritage or religion if it's relevant to the content."
Likewise, when talking about skin colour, the style guide asks to use terms that are easy to understand including brown and black skin. "We do not refer to brown or black skin as 'dark' or 'darker'."
It advises not to describe people as mentally ill but use phrases such as 'mental health condition' or 'mental health problems'.
Indian authorities have cancelled or suspended licences of some domestic drug companies as part of action taken against 76 pharmaceutical firms this month for
selling adulterated or fake products, a government source said on Thursday.
India is known as the 'pharmacy of the world' and its pharmaceuticals exports have more than doubled over the past decade to $24.5 billion in 2021-22.
But that image has been dented by the death of at least 70 children in Gambia and 19 children in Uzbekistan in Uzbekistan last year linked to drugs made by
India-based pharmaceutical companies.
Health Minister Mansukh Mandaviya confirmed a crackdown but did not give details of companies against which action had been taken.
"There are more than 10,500 pharma companies in the country. Companies who make spurious medicine will not be spared," Mandaviya told reporters at an event.
Licences of some Indian drug companies have been cancelled, some were suspended while others have been put on notice during the past 15 days, the source, who had
direct knowledge of the matter, told Reuters news agency.
The lessons from Covid crisis applied in the future through collaboration can create a better integration between GP practices, hospitals and community
pharmacies, Pharmacists Defence Association (PDA) has proposed.
Stating that a more integrated healthcare system could enable pharmacists to provide effective and more efficient care to patients, the PDA proposed a model where
at least two pharmacists would be working in each community pharmacy, empowered, and enabled with two-way referral pathways, having more clinical input and full
access to patient records.
"Such an environment could not only help to improve communications between health professionals and increase access to services for patients, but would support
the NHS to operate more effectively."
Pharmacy wholesaler PHOENIX UK is investing over £13 million to build a new state-of-the-art distribution hub in Wakefield.
The 260,000 sq. ft facility is expected to be operational next year and will service community pharmacies, hospitals and dispensing doctors across the North East
of England and Yorkshire.
In a statement on Tuesday (July 5), PHOENIX UK said the completed hub will feature 22 dock level loading bays and seven access doors to enable the productive arrival
and distribution of medical products.
It will also be highly energy efficient, including the use of Solar PV on its roof. The car park will also offer 46 electric vehicle charging bays.
Speaking at an official opening event held on 30 June to mark the expansion of the company's distribution capabilities, group managing director of PHOENIX Steve
Anderson said: "Over the last few years, we have seen an outstanding growth in customer demand for our core services outpacing the market: Wakefield is a prime
example of how we are committed to investing in the future by expanding our UK-wide operational capabilities to offer all our customers across the country the
best possible service they need, want and deserve.
Paul Rees MBE has joined the National Pharmacy Association (NPA) today (27 November) as its new Chief Executive.
Current NPA Chief Executive Mark Lyonette, who is retiring, will remain at the NPA for some weeks in order to ensure a smooth handover.
Previously, Paul has worked as the Chief Executive of the Royal College of Psychiatrists for the seven years.
On joining NPA, Paul said: "It is a great privilege and honour to take up the position of NPA Chief Executive. The association is the voice of independent
community pharmacy and is core to the sector's future success in England, Scotland, Wales and Northern Ireland.
"I am delighted that the NPA has placed its trust in me and I intend to deliver for NPA members, for the sector and for society at large, which relies on there
being a vibrant community pharmacy network in villages, towns and cities across the four nations of the UK."
When Paul's appointment was first announced in September, NPA Chair Nick Kaye said that they identified him as an "excellent fit for our organisation" after a
rigorous recruitment process, and also thanked Mark for his "great work as chief exec since 2018."
Boots is planning to invest more than £3.5 million to accelerate its capacity to offer prescribing services in its stores across England.
The company is inviting 500 of its pharmacists to apply for a bursary which will cover the cost of pharmacist independent prescriber (PIP) courses starting this
September.
The value of the bursary is up to £7,000 per pharmacist, and it will enable time off work for those who need it to complete the training.
The move by Boots will support its current pharmacists to gain this qualification via courses accredited by the General Pharmaceutical Council (GPhC). From 2026,
all qualified pharmacists will be able to prescribe as part of new curricula for pharmacy degrees.
Under current GPhC guidelines and with an independent prescribing qualification, pharmacists can prescribe autonomously for any condition within their clinical
competence.
Marc Donovan, the chief pharmacist at Boots, said the ambition of the company was "to have a pharmacist prescriber available at every store".
The Royal Pharmaceutical Society (RPS) England director, Ravi Sharma, has resigned after four years on the job.
He will be leaving the RPS in October to join Luton and Dunstable University Hospital, part of the Bedfordshire Hospitals NHS Foundation Trust group, as head of
pharmacy.
RPS will be commencing the recruitment of a new director for England shortly and in the interim Ravi will be working with Paul Bennett, the RPS CEO, to help in
delivery of key objectives and in the appointment of his successor.
Paul commented: "Ravi has made a significant contribution to the organisation during his time with us. His drive and enthusiasm for advancing the recognition of
the role of the Society itself and of pharmacists and professional practice is probably best reflected by his desire to ensure a real focus on personalised medicines
and his work on equality and diversity, workforce wellbeing, and most recently the development of a new vision for pharmacy in England.
While responding to the consultation on hub and spoke dispensing, trade unions for pharmacists have emphasised that the patient safety and care must be the priority in hub and spoke dispensing.
The Royal Pharmaceutical Society (RPS) has welcomed the opportunity provided by a change in legislation to enable community pharmacies to make use of hub and spoke
dispensing but reaffirmed that patient care must be at the heart of future changes.
With regards to patient safety, the Pharmaceutical Services Negotiating Committee (PSNC) considers that only Model 1 is appropriate, with manageable risks related
to patient safety, and is a model that has the potential to allow the whole sector to benefit fairly.
In its response to the consultation on Hub and Spoke dispensing, PSNC highlighted that Model 2 in the consultation, a hub direct to patient supply of dispensed medicines, raises patient safety issues and it cannot be supported.
RPS President Professor Claire Anderson said: "In all models, patients need to continue to have access to a pharmacist at the time of supply of medicines so they
have the opportunity to discuss, ask questions or raise concerns, and receive appropriate information with counselling and advice.
The National Pharmacy Association (NPA) Board has elected 14 Board members on Friday (30 March) that will govern the association for next two years.
Four new Board members have been elected while five previous members left the Board after serving their terms. The period April 2023 to March 2025 will see the
completion of the transition to the new Board structure.
The Board will meet again on Monday (24 April) to elect the Chair and other appointments.
Gareth Jones, Returning Officer for the NPA Board elections, said: "The NPA has undertaken a process of significant modernisation of organisational governance over
the past years. Key elements of this process include adopting modern new Articles of Association, reforming the structure of the Board and introducing term limits.
The process of electing the Board has also been changed so that half of the Board will be up for election every two years - which supports continuity and reduces the
risk of a loss of organisational memory."
"Recognising that the Board would already be losing a lot of organisational memory in 2023 with five members of Board standing down, the Board determined that three
individuals should be co-opted onto the new Board as the process of transformation continues. In March 2025, anyone that has served 12 years or more will be required
to stand down."
LloydsPharmacy has offered three per cent increase in base pay backdated to 1 April for its store pharmacists, the union of Pharmacists' Defence Association
(PDAU) who represented them has announced.
"We are pleased to announce that following a consultation of its members, the PDAU has informed the company that agreement can be reached on the company's latest
offer, made in July 2022," said the PDAU.
The offer made by the company also includes introduction of an overtime rate of 1.5 times basic pay for each hour worked after contracted hours. This will run for
a trial period and be reviewed as part of the next pay round.
"All pharmacists will receive an initial £1,000 payment under the proposed LTIP scheme, paid in April 2024. This will be to all in the bargaining unit and will not
be dependent on meeting any criteria such as targets," said PDAU.
AAH Pharmaceuticals on Tuesday (November 15) announced the promotion of its commercial director David Bound to chief executive officer of the company.
In his 10 years in the company, Mr Bound has helped to drive growth across the AAH business, implementing new digital channels for customers, and developing
strategic partnerships with pharmaceutical manufacturers - drawing on from his vast experience in the healthcare industry, as well as in supply chain, operations,
and trading.
Commenting on his promotion, he said: "I'm delighted to be taking on this role at such a critical time for healthcare. There are many challenges affecting the
industry right now - from inflationary pressures to workforce issues - and I'm looking forward to tackling them head-on alongside my excellent team."
The General Pharmaceutical Council (GPhC) today decided to convene a new group, involving all the key stakeholders, focused on assurance of practice post-registration.
The decision in today's (9 December) council meeting follows the recommendation of a working group chaired by council member and pharmacist Aamer Safdar on the role of the regulator in post-registration education and training.
The new group will be tasked with articulating a set of guiding principles where patient safety is the overarching priority, after carrying out a horizon scanning exercise to pull together an understanding of the system wide approach currently in place.
The working group noted that the wider approach, in relation to regulation of post-registration practice and not simply education and training, may require the GPhC reviewing and developing its own control measures, and involving patients and the public in the next stages of work.
Reviewing the work on online pharmacy services, the council meeting supported the regulator's plans to continue to require pharmacy websites to be arranged so that a person cannot choose a prescription only medicine and its quantity before there has been an appropriate consultation with a prescriber.
Two weeks prior to the closing of the hub and spoke consultation, issues around patient safety, costs and competition as well as practicalities such as what
to do with uncollected medicines were discussed in a webinar on hub and spoke dispensing on Wednesday (May 26).
The webinar was organised by Sigma Pharmaceuticals in association with the National Pharmacy Association (NPA).
NPA director of corporate affairs Gareth Jones chaired the event and was joined by Sigma's Hatul Shah and Raj Haria as well as NPA vice chair Nick Kaye and NPA
head of advice and support services Jasmine Shah.
Kaye said: "There are still many 'unknown unknowns' with hub and spoke and the jury's still out on any potential benefits. I have lots of reservations about cost
and it worries me how efficient this is for the business and the long term sustainability for the sector as a whole. Above all we need to think about the patient
at the centre of all this and the potential confusion for them."
Jasmine Shah felt patient safety was going to be the key in regards to whether the spoke and the hub would hold the ultimate responsibility and "who is going to
take the accountability as far as patient care goes".
She added: "It is most important that GPhC standards and NHS requirement are both met in identifying all the risks associated with the arrangement with hub and
spoke and ensuring that (patient safety) measures are in place. Everything that needs to be looked at is by putting the patient at heart of the arrangement and
seeing what is the safest way for them to receive care from both spoke and hub."
Usdaw, one of the major trade unions in the UK, has sought assurances for its members working in Boots, following reports that the parent company of the iconic health and beauty retailer and pharmacy chain is considering putting the business on sale next year.
Walgreen Boots Alliance (WBA), the US health group that owns a stake in Boots UK since 2012, is reportedly lining up Goldman Sachs to explore the sale of business
with potential valuation of £10 billion.
Currently, the process is thought to be solely exploratory and may not necessarily convert into the sale of the 172-year-old firm.
Usdaw national officer, Daniel Adams, said: "We note that the company declined to comment on speculation, but acknowledged that the group's strategic direction 'includes a more pointed focus on North America and on healthcare'.
After a series of internal pay negotiations and conciliation meetings, Boots has made a revised pay offer to its pharmacists.
With the new development, the Pharmacists' Defence Association (PDA) has urged its members at Boots to "urgently respond to the Boots pay negotiations update survey on the current pay offer."
It encouraged the members to complete the short survey sent to them via email.
Last week, the PDA Reps Network in Boots hosted a series of virtual meetings for members that work at the company.
As the element of the negotiations with Advisory, Conciliation and Arbitration Service (ACAS) are ongoing, PDA could not provide more details about these meetings.